Cantor Fitzgerald Reiterates Overweight Rating on NeuroPace Inc (NPCE)

Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $16.00 price target on NeuroPace Inc (NASDAQ: NPCE).

NeuroPace (NPCE, OW) announced preliminary one-year results from its NAUTILUS study evaluating the RNS
System in patients with idiopathic generalized epilepsy (IGE). While the study did not meet its primary effectiveness
endpoint in the overall population—defined as a statistically significant delay in time to second seizure for the active
stimulation group versus the sham group—important subgroup data suggest a clinically meaningful impact.

For an analyst ratings summary and ratings history on NeuroPace Inc click here. For more ratings news on NeuroPace Inc click here.

Shares of NeuroPace Inc closed at $13.22 yesterday.

You May Also Be Interested In

• NeuroPace (NPCE) Reiterated at Overweight by Cantor Fitzgerald on Commercial Momentum
• Bernstein SocGen: 'Investor day makes us more bullish on SanDisk (SNDK)'
• Benchmark Reiterates Hold Rating on VolitionRX (VNRX)